test

Research & Education | Clinical Trials | Active Trials | Trial

Prospective, Longitudinal, Multinational Registry of Patients with Newly Diagnosed Peripheral T-Cell Lymphoma

Conditions

Peripheral T-cell Lymphoma

Trial Phase

N/A

Trial Purpose and Description

Trial Purpose

The COMPLETE registry is a prospective, longitudinal, multinational, observational study that will collect data on how patients with peripheral T-cell lymphoma (PTCL) are treated in academic and community practices. The registry will enroll newly-diagnosed patients with PTCL treated with a variety of regimens. The COMPLETE registry is designed to better understand PTCL patient characteristics, treatments, and outcomes to help design and understand future clinical trials.


Participation Guidelines

Age:
Gender:
Both

Eligibility Criteria


Inclusion Criteria:

- Patient is newly diagnosed with Peripheral T-cell Lymphoma (PTCL):

- Aggressive natural killer (NK)-cell leukemia

- Adult T-cell lymphoma/leukemia (human T-cell leukemia virus [HTLV] 1+)

- Angioimmunoblastic T-cell lymphoma

- Anaplastic large cell lymphoma (ALCL), primary systemic type (ALK+, ALK-)

- PTCL, not otherwise specified (NOS)

- T/NK-cell lymphoma, nasal type

- Enteropathy-type intestinal lymphoma

- Hepatosplenic T-cell lymphoma

- Subcutaneous panniculitis T-cell lymphoma

- Transformed mycosis fungoides (at diagnosis of transformation)

- T-cell prolymphocytic leukemia (T-PLL)

- Cutaneous gamma/delta (?/d) T-cell lymphoma

- Cutaneous aggressive CD8+ T-cell lymphoma

- Hematodermic neoplasms (blastic plasmacytoid dendritic cell neoplasm)

- Systemic Epstein Barr Virus (EBV)+ T-cell lymphomas (T-cell lymphoproliferative
disorders of childhood)

- Other T-Cell lymphomas that are not listed in the Exclusion Criteria

- Patient gives written informed consent

Exclusion Criteria:

- Patient has other T- or NK-cell malignancies including:

- Precursor T/NK neoplasms

- T-cell large granular lymphocytic leukemia

- Mycosis fungoides, other than transformed mycosis fungoides

- S2zary syndrome

- Primary cutaneous CD30+ disorders: ALCL and lymphomatoid papulosis
Sponsor:
Spectrum Pharmaceuticals, Inc
Dates:
February 2010
Last Updated:
May 8, 2013
Study HIC#:
1008007318

Clinicaltrials.gov ID: NCT01110733